HUP0000809A2 - Hosszan ható hatóanyagok és azokat tartalmazó gyógyszerkészítmények - Google Patents

Hosszan ható hatóanyagok és azokat tartalmazó gyógyszerkészítmények Download PDF

Info

Publication number
HUP0000809A2
HUP0000809A2 HU0000809A HUP0000809A HUP0000809A2 HU P0000809 A2 HUP0000809 A2 HU P0000809A2 HU 0000809 A HU0000809 A HU 0000809A HU P0000809 A HUP0000809 A HU P0000809A HU P0000809 A2 HUP0000809 A2 HU P0000809A2
Authority
HU
Hungary
Prior art keywords
insulin
fmoc
group
radical
amino
Prior art date
Application number
HU0000809A
Other languages
English (en)
Hungarian (hu)
Inventor
Matityahu Fridkin
Eytan Gershonov
Yoram Shechter
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Publication of HUP0000809A2 publication Critical patent/HUP0000809A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HU0000809A 1996-08-07 1997-08-05 Hosszan ható hatóanyagok és azokat tartalmazó gyógyszerkészítmények HUP0000809A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11902996A IL119029A0 (en) 1996-08-07 1996-08-07 Long-acting drugs and pharamaceutical compositions comprising them
PCT/IL1997/000265 WO1998005361A2 (en) 1996-08-07 1997-08-05 Long-acting drugs and pharmaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
HUP0000809A2 true HUP0000809A2 (hu) 2000-11-28

Family

ID=11069166

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000809A HUP0000809A2 (hu) 1996-08-07 1997-08-05 Hosszan ható hatóanyagok és azokat tartalmazó gyógyszerkészítmények

Country Status (18)

Country Link
US (1) US6504005B1 (cg-RX-API-DMAC10.html)
EP (1) EP1019089B1 (cg-RX-API-DMAC10.html)
JP (1) JP4416184B2 (cg-RX-API-DMAC10.html)
KR (1) KR20000029806A (cg-RX-API-DMAC10.html)
CN (1) CN1227501A (cg-RX-API-DMAC10.html)
AT (1) ATE308998T1 (cg-RX-API-DMAC10.html)
AU (1) AU725468B2 (cg-RX-API-DMAC10.html)
BR (1) BR9711045A (cg-RX-API-DMAC10.html)
CA (1) CA2261835C (cg-RX-API-DMAC10.html)
CZ (1) CZ36999A3 (cg-RX-API-DMAC10.html)
DE (1) DE69734607T2 (cg-RX-API-DMAC10.html)
DK (1) DK1019089T3 (cg-RX-API-DMAC10.html)
ES (1) ES2252787T3 (cg-RX-API-DMAC10.html)
HU (1) HUP0000809A2 (cg-RX-API-DMAC10.html)
IL (3) IL119029A0 (cg-RX-API-DMAC10.html)
NO (1) NO990518L (cg-RX-API-DMAC10.html)
NZ (1) NZ333845A (cg-RX-API-DMAC10.html)
WO (1) WO1998005361A2 (cg-RX-API-DMAC10.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139400A0 (en) * 2000-11-01 2001-11-25 Yeda Res & Dev Long-acting cytokine derivatives and pharmaceutical compositions comprising them
AU2002239384B2 (en) * 2000-12-13 2007-01-11 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
EP1446103B1 (en) * 2001-10-19 2015-12-23 Idexx Laboratories, Inc. Injectable compositions for the controlled delivery of pharmacologically active compound
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
JP4033382B2 (ja) * 2002-04-08 2008-01-16 久光製薬株式会社 インスリン投与装置
WO2004064972A2 (en) * 2003-01-16 2004-08-05 Hk Pharmaceuticals, Inc. Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
PL1620118T3 (pl) * 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
DK1615632T3 (da) * 2003-04-17 2007-04-10 Jallal Messadek Flydende orale formularer for kontrolleret udskillelse af betain
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
US7282487B2 (en) * 2004-10-28 2007-10-16 Idexx Laboratories Method for treating bacterial infections in horses or pigs with tilmicosin
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
CN101180073A (zh) * 2005-04-27 2008-05-14 贾拉尔·梅萨德克 胰岛素组合
DK1969004T3 (da) * 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
KR101755434B1 (ko) 2008-03-18 2017-07-10 노보 노르디스크 에이/에스 프로테아제 안정화되고, 아실화된 인슐린 유사체
CN102076331B (zh) 2008-06-26 2013-12-18 普罗林科斯有限责任公司 具有可控的药物释放速率的前药和药物-大分子轭合物
WO2010033220A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2010033240A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
AU2009307729B2 (en) 2008-10-21 2015-09-17 Nektar Therapeutics Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-PEGylation)
BRPI0919946A2 (pt) * 2008-10-30 2016-02-16 Novo Nordisk As tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
RU2011140219A (ru) 2009-03-05 2013-04-10 Асцендис Фарма Ас Пролекарства интерферона альфа на носителе
WO2011013128A2 (en) 2009-07-31 2011-02-03 Yeda Research And Development Co. Ltd. Vectors for delivery of neurotherapeutics to the central nervous system
JP5977229B2 (ja) * 2010-05-05 2016-08-24 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放
HRP20191793T1 (hr) 2010-10-27 2019-12-27 Novo Nordisk A/S Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja
EP2490378B1 (en) 2011-02-18 2014-07-09 NTT DoCoMo, Inc. Apparatus and method for determining a control unit using feasibility requests and feasibility responses
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
BR112013030933A2 (pt) 2011-06-02 2018-04-24 Prolor Biotech Inc agonistas do receptor de glp-1/glucágon de ação prolongada
KR20150002777A (ko) 2012-04-11 2015-01-07 노보 노르디스크 에이/에스 인슐린 제제
CN104684576B (zh) 2012-06-04 2019-08-06 奥普科生物制品有限公司 聚乙二醇化的oxm变体
EP2869830B1 (en) 2012-07-09 2016-10-12 Novo Nordisk A/S Novel use of insulin derivatives
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
DK3554534T3 (da) 2016-12-16 2021-08-23 Novo Nordisk As Farmaceutisk sammensætning omfattende insulin
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
US20200254065A1 (en) 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
CN117551008B (zh) * 2023-11-10 2025-10-17 沈阳药科大学 一种去铁胺偶联物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU906341D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Process for producing peptonic derivatives modified with sugar and pharmaceutical preparatives containing these compounds as active substance
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US6313094B1 (en) * 1990-12-11 2001-11-06 Japan Energy Corporation β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
JPH0687887A (ja) * 1992-08-19 1994-03-29 Upjohn Co:The ペプチドのエナミン誘導体およびそれをプロドラッグとして含有するペプチド製剤
US5631222A (en) 1993-06-25 1997-05-20 Kyowa Hakko Kogyo Co., Ltd. Endothelin-antagonizing peptide
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
AU1919595A (en) 1994-02-09 1995-08-29 Brigham And Women's Hospital Gel-forming polypeptide derivatives
DE4437604A1 (de) * 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
WO1996030267A2 (en) * 1995-03-30 1996-10-03 Southpac Trust International, Inc. Self-erecting container which is collapsible to be substantially flat
US5688992A (en) * 1995-03-31 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof
US5846934A (en) * 1996-02-20 1998-12-08 American Cyanamid Company Pure somatostatin antagonist and methods of use thereof
US6057297A (en) * 1996-08-06 2000-05-02 Polifarma S.P.A. Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof

Also Published As

Publication number Publication date
US6504005B1 (en) 2003-01-07
CN1227501A (zh) 1999-09-01
DK1019089T3 (da) 2006-03-13
BR9711045A (pt) 1999-08-17
CA2261835C (en) 2008-07-29
CA2261835A1 (en) 1998-02-12
IL128274A0 (en) 1999-11-30
IL128274A (en) 2006-08-01
IL119029A0 (en) 1996-11-14
EP1019089B1 (en) 2005-11-09
WO1998005361A2 (en) 1998-02-12
NZ333845A (en) 2000-09-29
EP1019089A2 (en) 2000-07-19
NO990518L (no) 1999-04-06
JP2000515542A (ja) 2000-11-21
WO1998005361A3 (en) 1998-06-18
KR20000029806A (ko) 2000-05-25
ATE308998T1 (de) 2005-11-15
CZ36999A3 (cs) 1999-07-14
JP4416184B2 (ja) 2010-02-17
DE69734607T2 (de) 2006-08-03
AU3706097A (en) 1998-02-25
AU725468B2 (en) 2000-10-12
DE69734607D1 (de) 2005-12-15
NO990518D0 (no) 1999-02-04
ES2252787T3 (es) 2006-05-16

Similar Documents

Publication Publication Date Title
HUP0000809A2 (hu) Hosszan ható hatóanyagok és azokat tartalmazó gyógyszerkészítmények
EP1969004B1 (en) Compositions comprising an acylated insulin and zinc and method of making the said compositions
ES2526924T3 (es) Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
JP5220410B2 (ja) インスリン−オリゴマー複合体、その処方物及び使用
ES2390270T3 (es) Compuestos de GLP-1 unidos a polietilenglicol
EP2107069B1 (en) Novel insulin derivatives
US8722620B2 (en) Insulin derivatives
ES2548304T3 (es) Análogos de la insulina que contienen una fracción acilo y alquilenglicol
EP2437786B1 (en) Prodrugs containing albumin binding probe
CN110022902A (zh) 包含glp-1/胰高血糖素双重激动剂、接头和透明质酸的缀合物
WO2002008250A2 (en) Ghrelin antagonists
JP2008504249A (ja) 糖尿病を治療するための方法
KR20090043510A (ko) 펩타이드의 지속 방출 전달을 위한 약학적 조성물
HUP0004096A2 (hu) A humán inzulinszármazékok aggregátumai és ezeket tartalmazó gyógyszerészeti készítmény
CN116419750A (zh) 改进的glp-1受体激动剂的药物制剂
US20030162721A1 (en) Pharmaceutical composition containing peptichemio
JPH0667832B2 (ja) 腫瘍性疾患の治療に用いるプログルミド含有医薬組成物
CN119454605B (zh) 一种实现多肽口服吸收的组合物
US6740639B1 (en) Inclusion complees of a high potent opioid peptide, pharmaceutical compositions and method of treatment
Gershonov Novel strategy for preparation of long-acting drugs: Studies on insulin
WO2019037393A1 (zh) 一种对glp-1受体具有高亲和性的多肽化合物及其制备方法和应用
CN1964989B (zh) 长效胰岛素衍生物及其方法